Compare Tango Therapeutics Inc. (TNGX) vs The Travelers Companies Inc. Common Stock (TRV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs The Travelers Companies Inc. Common Stock — how do they compare? Tango Therapeutics Inc. trades at $22.2 (market cap $3.74B), while The Travelers Companies Inc. Common Stock trades at $380 (market cap $78.80B). The key difference: The Travelers Companies Inc. Common Stock is far larger — about 21.1× Tango Therapeutics Inc.'s market cap, and The Travelers Companies Inc. Common Stock pays a 1.32% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and The Travelers Companies Inc. Common Stock for 6 Days on average.
| TNGX | TRV | |
|---|---|---|
Market Cap | $3.74B | $78.80B |
Volume | 3,438,781 | 1,311,474 |
Sector | Health | Financials |
52-Week High | $32.90 | $397.22 |
52-Week Low | $7.50 | $261.57 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $2.76B | $87.39B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
TRV trades at $373.28, up 0.43% with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with a P/E of 10.03 and ROE of 26.32%, while consistently beating earnings estimates in recent quarters. Recent news highlights Travelers' earnings momentum ahead of Q3 results.
The outlook remains positive given valuation attractiveness and earnings beat history, though risks include competitive pressures and potential earnings volatility. Analyst consensus is mixed with 25% buy ratings but a $353.80 price target below current levels, suggesting cautious optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About The Travelers Companies Inc. Common Stock
The Travelers Companies provides property and casualty insurance for individuals, businesses, and organizations. Its products include auto, home, and commercial coverage.
Read more on TRV →
